一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Inavolisib；Fulvestrant；Alpelisib；Bupropion；Omeprazole；Midazolam，当前状态为招募中。登记地点显示中国长春、成都、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Inavolisib；Fulvestrant；Alpelisib；Bupropion；Omeprazole；Midazolam · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Hospital of Jilin University · 长春
- Sichuan Provincial Cancer Hospital · 成都
- The First Affiliated Hospital, Chongqing Medical University · 重庆
- Sun yat-sen University Cancer Center · 广州
- Guangdong Provincial People's Hospital · 广州
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
- Sir Run Run Shaw Hospital Zhejiang University · 杭州
- Harbin Medical University Tumor Hospital · 哈尔滨
- Shandong Cancer Hospital · 济南
- The Second Affiliated Hospital to Nanchang University · 南昌
- Jiangsu Cancer Hospital · 南京
- Tianjin Cancer Hospital · 天津
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University · 西安
- Zhejiang Cancer Hospital · 浙江省
公开的入选条件
- for Main Study and Sub-study:
- * If pre/perimenopausal women and men treatment with luteinizing hormone-releasing hormone (LHRH) agonist therapy beginning at least 2 weeks prior to Day 1 of Cycle 1
- * Histologically or cytologically confirmed adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent
- * Documented HR +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
- * Confirmation of biomarker eligibility: detection of specified mutation(s) of PIK3CA via specified test
- * Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 2 prior lines of systemic therapy in mBC setting; CDK4/6i based therapy does not need to be the last one received prior study entry; one line of chemothera
- * Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- * Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05646862；登记信息更新于 2026-09-28。